CRUK selects Medidata’s cloud-based system for cancer clinical trials
Dr. Nigel Blackburn, director of Cancer Research UK’s CDD, said: “Medidata’s cloud-based platform provides us with the flexibility and scalability we need to accelerate progress across all our trials.”
Cancer Research UK has selected Medidata Clinical Cloud to support its ground-breaking drug discovery research.
Cancer Research UK’s Centre for Drug Development (CDD) translates exciting new discoveries made in the lab into cutting-edge new cancer treatments for patients.
To further this work, the CDD is leveraging Medidata’s cloud-based technology for electronic data capture and management to conduct faster, safer clinical trials at institutes, universities and hospitals across the UK.
Medidata’s cloud-based system, will allow the CDD to make clinical data from its future trials easily accessible to researchers in real time, streamlining the process of setting up and running cancer trials. It will improve data quality, allow clinicians to easily monitor patients’ safety and enable more insightful decision making across all CDD trials.
Dr. Nigel Blackburn, director of Cancer Research UK’s CDD, said: “Medidata’s cloud-based platform provides us with the flexibility and scalability we need to accelerate progress across all our trials. Having immediate access to high-quality data will ultimately help us shorten trial delivery times, reduce costs and maximise the output of studies so that we can accelerate progress and bring new treatments to cancer patients sooner.”
“Transitioning to Medidata’s software-as-a-service platform for clinical trial management and execution—and partnering with a technology company that really understands our mission and R&D needs—will further increase collaboration between our research partners, especially those in the academic space.”